Invesco’s MiNK Therapeutics INKT Stock Holding History

Invesco’s Portfolio INKT Stock Details INKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,107	Closed	-$94K	–	4050
2021 Q4	$94K	Buy	+2,107	New	+$251K	﹤0.01%	3911

Other funds holding INKT

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Invesco's INKT Position: Q1 2022 in Review

Invesco sold out of MiNK Therapeutics (INKT) in Q1 2022, closing a stake of 2,107 shares — an estimated $94K sold.

Invesco first reported a position in INKT in Q4 2021 and held it in 1 quarter. The position peaked at $94K in Q4 2021. 25 funds tracked by Wall St. Rank hold INKT as of Q1 2022.

Invesco reported no remaining MiNK Therapeutics position as of Q1 2022 after selling out during the quarter.
Invesco sold 2,107 MiNK Therapeutics shares in Q1 2022, an estimated $94K.
Invesco first reported a position in MiNK Therapeutics in Q4 2021 and held it in 1 quarter.
Invesco's MiNK Therapeutics position peaked at $94K in Q4 2021.
25 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q1 2022.

Based on Invesco's 13F filing for Q1 2022, filed 16 May 2022.